BCL9 and non-small cell lung carcinoma: It has been found that in non-small cell lung cancer (NSCLC), PBDs can increase intracellular B-cell CLL/lymphoma 9 (BCL9) expression and form the β-catenin/BCL9 complex by selectively binding to the N-terminal structural domain of β-catenin.